Piper Sandler Issues Pessimistic Forecast for TransMedics Group (NASDAQ:TMDX) Stock Price

TransMedics Group (NASDAQ:TMDX) had its price target decreased by investment analysts at Piper Sandler from $160.00 to $120.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler’s price target would suggest a potential upside of 63.80% from the stock’s previous close.

Several other brokerages have also issued reports on TMDX. Wall Street Zen lowered TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. TD Cowen reaffirmed a “buy” rating on shares of TransMedics Group in a research note on Monday, March 16th. Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a research note on Wednesday. JPMorgan Chase & Co. lifted their price target on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Finally, Stifel Nicolaus lifted their price target on TransMedics Group from $115.00 to $130.00 and gave the stock a “hold” rating in a research note on Monday, March 9th. Six equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, TransMedics Group has a consensus rating of “Moderate Buy” and a consensus target price of $144.33.

TransMedics Group Price Performance

TMDX stock traded down $21.67 during mid-day trading on Wednesday, hitting $73.26. 3,976,214 shares of the stock were exchanged, compared to its average volume of 934,086. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59. The business has a fifty day moving average price of $116.57 and a 200 day moving average price of $125.96. TransMedics Group has a 12 month low of $71.67 and a 12 month high of $156.00. The stock has a market capitalization of $2.53 billion, a price-to-earnings ratio of 14.90 and a beta of 2.07.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 30.17% and a net margin of 31.43%.The firm had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.48 million. During the same period last year, the firm earned $0.70 EPS. The company’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, sell-side analysts anticipate that TransMedics Group will post 2.48 EPS for the current year.

Insider Buying and Selling

In other news, CFO Gerardo Hernandez sold 7,236 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $147.21, for a total value of $1,065,211.56. Following the completion of the sale, the chief financial officer owned 14,689 shares of the company’s stock, valued at approximately $2,162,367.69. The trade was a 33.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David Weill sold 3,571 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $146.82, for a total value of $524,294.22. Following the completion of the sale, the director directly owned 12,134 shares of the company’s stock, valued at approximately $1,781,513.88. This trade represents a 22.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 16,205 shares of company stock worth $2,353,002 in the last 90 days. 6.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada increased its holdings in TransMedics Group by 47.9% during the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after purchasing an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after purchasing an additional 868 shares during the period. Goldman Sachs Group Inc. increased its holdings in TransMedics Group by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock valued at $34,145,000 after purchasing an additional 86,721 shares during the period. Russell Investments Group Ltd. increased its holdings in TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock valued at $1,059,000 after purchasing an additional 938 shares during the period. Finally, M&T Bank Corp purchased a new position in TransMedics Group during the 2nd quarter valued at about $209,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group News Roundup

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Solid top-line growth and strong profitability metrics: Q1 revenue rose ~21.2% year-over-year and the business reported a healthy net margin (31.4%) and ROE (~30%). These fundamentals support longer-term growth expectations. MarketBeat Q1 report
• Positive Sentiment: Needham kept a Buy rating and set a $142 price target (lowered from $174) — signaling continued analyst conviction and implying significant upside from current levels despite the cut. Benzinga note on Needham
• Neutral Sentiment: FY‑2026 revenue guidance was reiterated/updated to $727M–$757M (range that roughly brackets consensus), leaving investors to parse whether guidance implies conservatism or is in line with expectations. PR Newswire release
• Neutral Sentiment: Earnings call transcript and supplemental materials are available for details on product adoption, backlog and margin drivers—useful for modeling but not immediate market movers absent new guidance. Seeking Alpha transcript
• Negative Sentiment: Q1 EPS missed expectations: reported $0.30 vs. consensus ~$0.62 and sharply below last year’s $0.70, flagging pressure on near-term profitability per-share and driving immediate downside. Revenue also slightly missed consensus. Zacks coverage of the miss
• Negative Sentiment: Analyst downgrade from Oppenheimer (Outperform → Market Perform) adds selling pressure and reduces near-term enthusiasm from institutional buyers. Finviz note on downgrade

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.